Brief: Marker Therapeutics Appointed Eliot Lurier As Co's Interim CFO
03/07/2023 21:19
July 3 (Reuters) - Marker Therapeutics Inc MRKR.O :
* MARKER THERAPEUTICS INC - EFFECTIVE JUNE 30, 2023,
APPOINTED
ELIOT M. LURIER AS COMPANY'S INTERIM CHIEF FINANCIAL OFFICER
Source text for Eikon: ID:
Further company coverage: MRKR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Marker Therapeutics
See all newsBrief: Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant To Advance MT-601 In Pancreatic Cancer
Marker Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Marker Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview
Marker Therapeutics 2025 net loss widens, hurt by decline in grant income
Brief: Marker Therapeutics FY Basic EPS USD -0.79